Cantor Fitzgerald Reiterates Overweight Rating on AxoGen, Inc. (AXGN)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $24.00 price target on AxoGen, Inc. (NASDAQ: AXGN).

The analyst commented, "We reiterate our Overweight rating and $24 price target on Axogen's (AXGN) shares following the company's Investor Day where management laid out AXGN's detailed plan on expanding adoption within high potential accounts and expanding into the prostate market in addition to launching new products over the company's strategic plan (2025-2028E). Notably, Axogen’s estimates the company now addresses a $5.6 billion market opportunity (up from $2.7 billion previously) based on current product offerings and has developed a thoughtful operating plan to meet the company's goal of becoming the standard of care withing its market segments. Accordingly, with an expanding market opportunity, larger sales force and growing portfolio of products and supporting data, we believe AXGN is set up well to meet and exceed expectations."

For an analyst ratings summary and ratings history on AxoGen, Inc. click here. For more ratings news on AxoGen, Inc. click here.

Shares of AxoGen, Inc. closed at $18.62 yesterday.

You May Also Be Interested In

• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
• JPMorgan Starts Lotte Shopping Co Ltd (023530:KS) at Neutral
• JPMorgan Starts Shinsegae Inc (004170:KS) at Overweight